Needham & Company LLC Reiterates “Buy” Rating for BioCryst Pharmaceuticals (NASDAQ:BCRX)

BioCryst Pharmaceuticals (NASDAQ:BCRX)‘s stock had its “buy” rating reiterated by stock analysts at Needham & Company LLC in a research note issued to investors on Tuesday, Benzinga reports. They currently have a $14.00 target price on the biotechnology company’s stock. Needham & Company LLC’s price target points to a potential upside of 81.11% from the stock’s previous close.

BCRX has been the subject of several other research reports. Barclays raised their price objective on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the company an “equal weight” rating in a report on Tuesday. StockNews.com raised BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, August 6th. HC Wainwright reissued a “buy” rating and issued a $30.00 price objective on shares of BioCryst Pharmaceuticals in a report on Tuesday, August 6th. JMP Securities boosted their target price on shares of BioCryst Pharmaceuticals from $15.00 to $16.00 and gave the stock a “market outperform” rating in a report on Tuesday, August 6th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $10.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday, August 6th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $14.67.

BioCryst Pharmaceuticals Stock Performance

NASDAQ BCRX opened at $7.73 on Tuesday. The stock has a market capitalization of $1.60 billion, a price-to-earnings ratio of -12.67 and a beta of 1.89. BioCryst Pharmaceuticals has a 52 week low of $4.03 and a 52 week high of $8.88. The stock’s 50 day moving average price is $7.80 and its two-hundred day moving average price is $6.98.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings data on Monday, November 4th. The biotechnology company reported ($0.07) EPS for the quarter, hitting analysts’ consensus estimates of ($0.07). The business had revenue of $117.10 million during the quarter, compared to the consensus estimate of $113.99 million. The business’s revenue for the quarter was up 35.1% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.19) EPS. On average, equities research analysts forecast that BioCryst Pharmaceuticals will post -0.37 EPS for the current year.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

Several hedge funds have recently bought and sold shares of BCRX. CWM LLC grew its position in shares of BioCryst Pharmaceuticals by 200.0% in the second quarter. CWM LLC now owns 5,658 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 3,772 shares during the last quarter. Signaturefd LLC grew its holdings in BioCryst Pharmaceuticals by 560.5% in the 2nd quarter. Signaturefd LLC now owns 6,598 shares of the biotechnology company’s stock valued at $41,000 after buying an additional 5,599 shares in the last quarter. Seven Eight Capital LP bought a new position in BioCryst Pharmaceuticals during the 1st quarter worth $57,000. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of BioCryst Pharmaceuticals by 21.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company’s stock worth $57,000 after buying an additional 1,322 shares in the last quarter. Finally, Natixis boosted its position in shares of BioCryst Pharmaceuticals by 400.6% in the first quarter. Natixis now owns 11,684 shares of the biotechnology company’s stock valued at $59,000 after acquiring an additional 9,350 shares during the period. 85.88% of the stock is currently owned by institutional investors and hedge funds.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.